KDM4C and metastatic prostate carcinoma: Also the expression of KDM4C was higher in metastatic prostate cancer patients, and KDM4C knockdown or pharmacological inhibition using SD70 significantly reduced cell migration and invasion, which was associated with the increased level of E-cadherin [88].